DUREX presents new “Viagra Condoms”
“Can this “Viagra Condom” help promote safe sex?”
Well, if a longer erection can entice men to use this ever-essential sex-safety device, why not? Condoms, have usually been graded second to contraceptive pills, despite the protection they provide against STDs and STIs, but this innovative new product by a British biotech firm FUTURA MEDICAL called CSD500, helps men keep their erection longer. It incorporates a vasodilating gel, which increases blood flow to the penis and helps maintain erection. The gel is to be licensed under the trademarked brand name of Zanifil®.
By applying the CSD500 condom, a pharmacological dose contained within the teat of the condom will be delivered to the penis. This has been clinically proven to increase local blood flow within the penis which in turn leads to increased firmness, increased penile size and longer duration of an erection.
But unlike the pill, it’s not designed for men who have erectile dysfunction; rather, it’s meant for men who have trouble keeping erections specifically while using a condom. Futura has a global distribution agreement with the world’s largest branded condom manufacturer and distributor, Reckitt Benckiser Group plc (“RB” – makers of the Durex® condom range) for the lifetime of the patents.
In a double blind clinical study comparing CSD500 against a standard condom co-sponsored by Futura, of those who expressed a preference, a significant proportion of both men and women reported improvements in the firmness of the man’s erection during intercourse when using CSD500, compared against a standard condom. A result that was highly statistically significant.
Furthermore, of those who expressed a preference, a significant proportion of both men and women also felt that CSD500 increased the penis size and a significant proportion of women reported a longer lasting sexual experience with CSD500.
So how does Futura’s new invention work?
The trick is getting the gel to stay put inside the condom, so that it would not affect the condom-wearer’s partner. According to the Wall Street Journal report:
Finding an active ingredient was straightforward — it’s a generic compound for the treatment of angina, a severe chest pain caused by lack of blood flow to the heart. However, “immobilizing” the gel in the condom, so the vasodilator only touches the wearer during sexual intercourse, was the clever part.
“The challenge is having a stable product in a condom — a gel that doesn’t do anything detrimental to the condom,” Futura Chief Executive James Barder said.
“Some products can degrade the latex very quickly,” said Mr. Barder, noting that adding the vasodilator to the lubricant is complicated. “It has to be immobilized in the condom.” Most of the patents protecting CSD500 are associated with this immobilization, Mr. Barder said.
Although CSD500 isn’t meant to compete with Viagra and it is definitely, NOT A REPLACEMENT for Viagra (despite being created by the same developers), seeing the booming online sales of Viagra, it can be concluded that men would certainly give this erection-encouraging condom a shot.
Reckitt Benckiser plans to investigate the condom’s commercial viability in Europe if it is approved, and then expand to the U.S. market. Discussions with EU regulatory authorities have confirmed that the product will be classified within the EU as a Class III medical device with an ancillary medicinal substance. This classification will allow the product to be sold throughout Europe in the same way as conventional condoms.
Pingback: Does sex without a condom feel dramatically different than sex with? : Body Building Blog | Free Fitness Tips & Body Building…
Pingback: Ripped from the headlines
Pingback: Мягкая мебель для гостинной
Pingback: public liability insurance quote